WARNING Do NOT take Ozempic or Mounjaro until you watch this

A Pulmonologist's Warning: Sorting Hype From Real Risk

Dr. Mike Hansen is a pulmonologist and critical care physician whose YouTube channel has grown to a large following by covering medical topics with a blend of clinical authority and accessible delivery. This video, with its attention-grabbing title and over 747,000 views, walks through the risks and side effects of Ozempic and Mounjaro with more clinical detail than most patient-facing content. The clickbait title might make you expect fearmongering, but the actual content is more balanced than the packaging suggests.

Dr. Hansen starts with an important framing: GLP-1 drugs are effective medications backed by strong clinical evidence, and they have helped millions of people improve their metabolic health. But like any medication, they carry risks, and patients deserve to know those risks in detail before starting treatment. He then walks through the major categories of concern, from common GI side effects to rarer but more serious complications like pancreatitis, gallbladder disease, and the thyroid cancer question.

The video is structured as a risk-by-risk walkthrough, which is a useful format for patients who want to understand specific concerns. For each risk, Hansen provides the clinical evidence, the estimated frequency, and his clinical perspective on how seriously to take it. This structured approach helps viewers calibrate their concern levels rather than treating all side effects as equally alarming.

The Risk Rundown: What Deserves Your Attention

Hansen covers the GI side effects quickly since they are well known, and spends more time on the less common but more serious risks. Pancreatitis gets a detailed treatment. He explains that there is a biological rationale for concern, since GLP-1 receptors are found in the pancreas, and case reports of pancreatitis in GLP-1 users exist. However, the large clinical trials did not show a statistically significant increase in pancreatitis rates. His take is that the risk is real but low, and that patients with a history of pancreatitis or heavy alcohol use should be particularly cautious.

Gallbladder disease gets similar treatment. Rapid weight loss from any cause increases the risk of gallstones, and GLP-1-induced weight loss is no exception. Hansen notes that the clinical trials did show a higher rate of gallbladder events in the treatment groups. He recommends that patients be aware of gallbladder symptoms (right upper abdominal pain, especially after fatty meals, sometimes with nausea) and report them promptly.

The thyroid cancer discussion is handled well. The FDA-required boxed warning about medullary thyroid carcinoma (MTC) comes from rodent studies where GLP-1 drugs caused thyroid C-cell tumors in rats and mice. Hansen explains that human thyroid tissue has far fewer GLP-1 receptors than rodent tissue, and that epidemiological studies in humans have not confirmed an increased MTC risk. The warning exists out of an abundance of caution, not because of demonstrated human risk. That said, patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 should not take these drugs.

He also covers kidney effects, noting that dehydration from GI side effects (vomiting, diarrhea) can stress the kidneys, especially in patients who already have reduced kidney function. Staying hydrated and monitoring kidney function with routine bloodwork is the practical takeaway here.

What the Video Gets Right

Hansen's clinical background shows in the quality of the risk analysis. He does more than list side effects; he contextualizes them with incidence rates, biological plausibility, and clinical significance. This is exactly what patients need but rarely get from either their prescribers (who may downplay risks to encourage treatment) or from social media (which tends to amplify the scariest stories). The tone is neither dismissive nor alarmist, which is the sweet spot for medical education.

He also makes a point that resonates: the risks of GLP-1 drugs need to be weighed against the risks of untreated obesity and type 2 diabetes, which include heart disease, stroke, kidney failure, and shortened lifespan. No medication is risk-free, and the decision to use one should be based on comparing the risk of treatment to the risk of non-treatment, not on the risk of treatment in isolation.

What It Misses

Despite the balanced content, the title and thumbnail are classic clickbait, which sets an adversarial tone that the video itself does not sustain. Some viewers will click away before getting to the nuanced analysis, left only with the fear the title generates. This is a common YouTube problem, not specific to Dr. Hansen, but worth knowing.

The video does not cover drug interactions, compounding pharmacies, or the practical aspects of starting and managing these medications. It is purely a risk-assessment resource, which means you need other content for the full treatment picture. The weight-regain-after-stopping question also does not get attention, which is arguably the biggest long-term risk that patients should understand.

Questions to Bring to Your Doctor

This video prepares you to have a specific, risk-focused conversation:

Ask your doctor which of the risks discussed are most relevant to your personal medical history. A patient with a history of gallstones faces a different risk calculus than a patient with perfect gallbladder function.

Ask about the monitoring schedule. What bloodwork should be done before starting, and how often should it be repeated? At minimum, kidney function and pancreatic enzymes should be on the list.

Ask about the specific signs and symptoms that should prompt an immediate call or emergency visit versus those that can wait for a scheduled appointment.

Ask how the risks of the medication compare to the risks of your current health trajectory without treatment. This risk-benefit comparison is the foundation of any medication decision.

Who Should Watch This

This is a good pre-treatment video for anyone who wants to go into their first GLP-1 prescription with eyes open. It is also useful for patients who are already on these drugs and have encountered alarming headlines or social media posts about risks. Hearing a physician walk through each risk systematically, with actual clinical context, can either validate a concern that deserves attention or put an overblown fear to rest. Ignore the clickbait title and focus on the content, which is solid.

Hansen's point about comparative risk deserves special emphasis because it is the single most important concept in medication decision-making that patients often miss. Every medication carries risks. The question is never whether there are risks but whether the risks of treatment are smaller than the risks of not treating. For someone with a BMI over 35 and co-existing conditions like type 2 diabetes, hypertension, and sleep apnea, the risks of untreated obesity, including dramatically elevated rates of heart attack, stroke, kidney failure, and premature death, are substantial and well documented. Against that backdrop, the risks of GLP-1 medications, while real, need to be weighed proportionally.

The video's coverage of kidney-related concerns is particularly useful because it highlights a risk factor that is manageable with basic awareness. Dehydration is a real threat for patients experiencing vomiting or diarrhea from GLP-1 drugs, and it can push borderline kidney function into dangerous territory. The practical solution is straightforward: drink significantly more water than you think you need, monitor the color of your urine as a rough hydration indicator, consider electrolyte supplementation during periods of GI distress, and make sure your doctor is checking kidney function with routine bloodwork at appropriate intervals. These simple steps can prevent a manageable side effect from becoming a serious complication.

For patients with anxiety about starting these medications, Hansen's systematic approach can actually be calming rather than alarming, despite the provocative title. Knowing the specific risks, understanding how common they are, and having a monitoring plan in place replaces vague fear with concrete knowledge. Fear of the unknown is almost always more distressing than informed awareness of specific, manageable risks. If watching this video helps you develop a clear risk-monitoring plan with your doctor rather than avoiding treatment out of unspecified worry, it will have served its purpose well regardless of the clickbait packaging.

The gap between the video's title and its actual content is worth knowing for what it says about medical content on YouTube more broadly. The platform's algorithm rewards sensational titles and thumbnails, which means even serious, balanced creators feel pressure to package their content in alarming ways to compete for attention. As a viewer, learning to look past the packaging and evaluate the actual content is a valuable skill for navigating health information on YouTube. Hansen's content is solidly evidence-based despite the dramatic framing, and that disconnect between title and substance is something to be aware of as you evaluate other GLP-1 content on the platform.

The mental health dimension of starting a potent medication with known side effects also deserves mention. Health anxiety is real, and for patients who tend toward worry about medical issues, a video like this can either help (by providing concrete information that replaces vague fear) or hurt (by introducing new worries they had not previously considered). If you are someone who tends toward health anxiety, consider watching this video with a trusted friend or family member who can help you process the information proportionally rather than catastrophizing about rare risks. The goal is to be informed and appropriately cautious, not to add anxiety to an already complex treatment decision.

Dr. Hansen also makes a useful implicit point about the importance of choosing the right prescriber. A doctor who takes time to discuss risks in detail, who monitors you appropriately with regular lab work and follow-up appointments, and who is responsive when you report symptoms is your best protection against both common and rare adverse events. The quality of your prescriber relationship is arguably the most important safety factor in your entire GLP-1 treatment journey, more important than any individual risk factor the video discusses.